CDK2 and cancer: This has prompted the suggestion that the predominance of Cdk6–Cyclin D-p27 trimers depletes p27 from the pools of Cdk2 to elevate Cdk2 activities and confer palbociclib resistance in cancers in which Cdk6 expression is elevated [67,83,84].